Related Experiment Video
Updated: Oct 29, 2025

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Alkyl-Aryl-Vancomycins: Multimodal Glycopeptides with Weak Dependence on the Bacterial Metabolic State
Paramita Sarkar1, Debajyoti Basak1, Riya Mukherjee1
1Antimicrobial Research Laboratory, New Chemistry Unit and School of Advanced Materials, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur, Bengaluru 560064, Karnataka, India.
Abstract:
Resistance to last-resort antibiotics such as vancomycin for Gram-positive bacterial infections necessitates the development of new therapeutics. Furthermore, the ability of bacteria to survive antibiotic therapy through formation of biofilms and persister cells complicates treatment. Toward this, we report alkyl-aryl-vancomycins (AAVs), with high potency against vancomycin-resistant enterococci and staphylococci. Unlike vancomycin, the lead compound AAV-qC10 was bactericidal and weakly dependent on bacterial metabolism. This resulted in complete eradication of non-growing cells of MRSA and disruption of its biofilms. In addition to inhibiting cell wall biosynthesis like vancomycin, AAV-qC10 also depolarizes and permeabilizes the membrane. More importantly, the compound delocalized the cell division protein MinD, thereby impairing bacterial growth through multiple pathways. The potential of AAV-qC10 is exemplified by its superior efficacy against MRSA in a murine thigh infection model as compared to vancomycin. This work paves the way for structural optimization and drug development for combating drug-resistant bacterial infections.
Insights
New alkyl-aryl-vancomycins (AAVs) show potent activity against resistant bacteria. The lead compound AAV-qC10 eradicates biofilms and persister cells, offering a promising new therapeutic strategy for drug-resistant infections.
Area of Science:
- Microbiology
- Medicinal Chemistry
- Pharmacology
Background:
- Growing resistance to last-resort antibiotics like vancomycin is a major public health threat.
- Bacterial biofilms and persister cells pose significant challenges to conventional antibiotic therapies.
- Novel therapeutic agents are urgently needed to combat multidrug-resistant Gram-positive bacterial infections.
Purpose of the Study:
- To develop and characterize novel vancomycin derivatives with enhanced activity against resistant bacteria.
- To investigate the mechanism of action of these new compounds, focusing on their effects on bacterial metabolism, cell membranes, and growth.
Main Methods:
- Synthesis and characterization of alkyl-aryl-vancomycins (AAVs).
- In vitro testing of AAV potency against vancomycin-resistant enterococci and staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA).
- Assessment of AAV-qC10's bactericidal activity, metabolic dependence, biofilm disruption, membrane effects, and impact on the MinD protein.
- In vivo efficacy evaluation of AAV-qC10 in a murine thigh infection model.
Main Results:
- AAVs demonstrated high potency against vancomycin-resistant enterococci and staphylococci.
- The lead compound, AAV-qC10, exhibited bactericidal activity, was weakly dependent on bacterial metabolism, and eradicated non-growing MRSA cells.
- AAV-qC10 disrupted MRSA biofilms and exhibited dual action by inhibiting cell wall biosynthesis and disrupting the bacterial membrane.
- AAV-qC10 delocalized the MinD protein, impairing bacterial growth through multiple mechanisms.
- AAV-qC10 showed superior efficacy against MRSA in a murine thigh infection model compared to vancomycin.
Conclusions:
- Alkyl-aryl-vancomycins represent a promising new class of antibiotics effective against drug-resistant Gram-positive bacteria.
- AAV-qC10's multifaceted mechanism of action, including targeting biofilms and persister cells, offers a significant advantage over vancomycin.
- These findings support further development of AAVs for combating challenging bacterial infections and overcoming antibiotic resistance.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Effectiveness
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Antibiotic Selection
Gram-negative Bacterial Protein Secretion Systems
Gene Regulation in Microbial Communities: Quorum Sensing

